We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Credit Suisse Group | NYSE:CS | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.8858 | 0 | 01:00:00 |
From May 2019 to May 2024
Activist investor William Ackman's Pershing Square Capital Management LP on Monday put forth a slate of six nominees for Botox maker Allergan Inc.'s board.
Pershing has backed Valeant Pharmaceuticals International Inc.'s roughly $53 billion takeover bid for Allergan, which has rejected a series of offers from Valeant. Pershing owns a 9.7% stake in Allergan.
Pershing and Allergan agreed last month to a deal that allows Mr. Ackman and his firm to coordinate with shareholders to call a special meeting.
Last week, the Valeant bid received a vote of confidence from Credit Suisse Group AG as the bank agreed to advise Pershing in the Allergan bid.
Pershing's slate includes Betsy Atkins, Cathleen P. Black, Fredric N. Eshelman, Steven J. Shulman, David A. Wilson and John J. Zillmer. Pershing said the nominees are independent of Pershing and Valeant.
An Allergan representative didn't immediately respond to a request for comment.
Write to Michael Calia at michael.calia@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Credit Suisse Chart |
1 Month Credit Suisse Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
